β | 95% CI | P value | |
Age, years | −0.61 | −2.0 to 0.75 | 0.4 |
Male sex | −62 | −127 to 3.7 | 0.064 |
At least one BILAG score ≥B | −45 | −106 to 17 | 0.2 |
C3, g/L | 35 | −77 to 147 | 0.5 |
dsDNA antibodies, IU/mL | 0.04 | −0.06 to 0.13 | 0.4 |
Detectable IFN-α | −3.4 | −7.4 to 0.58 | 0.093 |
Total serum IgA, g/L | 1.8 | −12 to 16 | 0.8 |
Total serum IgG, g/L | 2.0 | 0.34 to 3.6 | 0.018 |
Total serum IgM, g/L | 12 | −1.0 to 24 | 0.071 |
Lymphocytes count, G/L | 6.6 | −31 to 44 | 0.7 |
Corticosteroids low | −20 | −66 to 26 | 0.4 |
Corticosteroids high | −50 | −127 to 28 | 0.2 |
Hydroxychloroquine | −27 | −85 to 31 | 0.4 |
Azathioprine | −118 | −242 to 6.5 | 0.063 |
Belimumab | −18 | −90 to 54 | 0.6 |
Mycophenolate mofetil | −78 | −133 to 22 | 0.007 |
Methotrexate | −122 | −184 to 61 | <0.001 |
Other immunosuppressor | 62 | −32 to 156 | 0.2 |
SLE activity is measured with BILAG score.
*See the Methods section.
BILAG, British Isles Lupus Assessment Group; dsDNA, double-stranded DNA; IFN, interferon; IgG, immunoglobulin G; RBD, receptor binding domain.